RANKL is a therapeutic target of bone destruction in rheumatoid arthritis [version 1; peer review: 2 approved]

• Main Author: Sakae Tanaka
• Format: Article
• Language: English
• Published: F1000 Research Ltd 2019-04-01
• Series: F1000Research
• Online Access: https://f1000research.com/articles/8-533/v1

Although remarkable advances have been made in the treatment of rheumatoid arthritis (RA), novel therapeutic options with different mechanisms of action and fewer side effects have been expected. Recent studies have demonstrated that bone-resorbing osteoclasts are critically involved in the bone destruction associated with RA. Denosumab, a human antibody against receptor activator of nuclear factor-kappa B ligand (RANKL), efficiently suppressed the progression of bone erosion in patients with RA by suppressing osteoclast differentiation and activation in several clinical studies, although it had no effect on inflammation or cartilage destruction. Denosumab, in combination with anti-rheumatic drugs, is considered a pivotal therapeutic option for the prevention of bone destruction in RA.